0
Deep & Emerging Tech·July 17, 2026·1 min read

Chip Stock Selloff Deepens in Asia as TSMC Fails to Impress

Share

Chip equities selling off on “strong but not strong enough” TSMC results is a reminder that public-market AI expectations are ahead of near-term profitability. Operators should not read this as a demand collapse—yet—but as a warning that capex-heavy bets will be judged brutally on utilization and margin.

Deep & Emerging Tech

Kalshi is offering wagers on the outcomes of late-stage clinical drug trials and regulatory decisions, launching a pilot of 13 new biotech contracts

Prediction markets on late-stage trials and FDA decisions turn biotech milestones into tradable signals—drug developers and funds now get a real-time, crowd-priced read on regulatory odds. Operators in pharma and biotech should expect their timelines and disclosures to be interpreted—and front-run—through this new market lens.